Cargando…

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade

SIMPLE SUMMARY: Not all cancer patients receiving immunotherapy by immune checkpoint blockade experience a clinical benefit. Our study was aimed at identifying biomarkers that could guide the selection of immunotherapy-responsive patients. Immunotherapy targets two major populations of lymphocytes:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez-Gomez, Carlos, Michelas, Marie, Scarlata, Clara-Maria, Salvioni, Anna, Gomez-Roca, Carlos, Sarradin, Victor, Lauzéral-Vizcaino, Françoise, Féliu, Virginie, Dupret-Bories, Agnès, Ferron, Gwénaël, Sarini, Jérôme, Devaud, Christel, Delord, Jean-Pierre, Balança, Camille-Charlotte, Martinez, Alejandra, Ayyoub, Maha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367599/ https://www.ncbi.nlm.nih.gov/pubmed/35954341 http://dx.doi.org/10.3390/cancers14153679

Ejemplares similares

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis
por: Bartosińska, Joanna, et al.
Publicado: (2018)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

Accumulation of CD5(+)CD19(+) B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils
por: Wlasiuk, Paulina, et al.
Publicado: (2015)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
por: Cassady, Kaniel, et al.
Publicado: (2018)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
por: Ma, Ke, et al.
Publicado: (2020)

PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates
por: Majer, Christiane, et al.
Publicado: (2023)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1(+) viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion
por: Correa-Rocha, Rafael, et al.
Publicado: (2018)

Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome
por: Han, Rui, et al.
Publicado: (2021)

Neuropilin-1 cooperates with PD-1 in CD8(+) T cells predicting outcomes in melanoma patients treated with anti-PD1
por: Rossignol, Julien, et al.
Publicado: (2022)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Restored CD8(+)PD-1(+) T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
por: Zhu, Qian, et al.
Publicado: (2022)

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
por: Saber, Manal Mohamed
Publicado: (2023)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

PD-1(+)CD8(+) T Cells Proximal to PD-L1(+)CD68(+) Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients
por: Yang, Xiaobao, et al.
Publicado: (2023)

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance
por: Baas, Marije, et al.
Publicado: (2016)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation
por: Liu, Li, et al.
Publicado: (2015)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Functional differences between PD-1(+) and PD-1(-) CD4(+) effector T cells in healthy donors and patients with glioblastoma multiforme
por: Goods, Brittany A., et al.
Publicado: (2017)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis
por: Rabe, Hardis, et al.
Publicado: (2014)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4(+) T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes
por: Pauken, Kristen E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r3ol775jk9edkmhiv4i229o1iv